Novel Vital-sign Patient-assisted Intravenous Analgesia With Remifentanil for Labour Pain to Reduce Maternal Desaturation and Improve Analgesic Titration: a Prospective Cohort Study

Trial Profile

Novel Vital-sign Patient-assisted Intravenous Analgesia With Remifentanil for Labour Pain to Reduce Maternal Desaturation and Improve Analgesic Titration: a Prospective Cohort Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Remifentanil (Primary)
  • Indications Labour pain
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 05 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 05 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top